When the efficacy of anti-EGFR agents versus Bevacizumab was analyzed according to tumor location, patients with LCC treated with Cetuximab or Panitumumab had a significantly longer median OS (40.7 vs 28.6 months; HR: 0.67; 95% CI 0.47 to 0.95; p= 0.026) and PFS (12.4 vs 10.7 months; HR: 0.69; 95% CI, 0.51 to 0.93; p= 0.015) (Figure 3 A and B). Here, EGFR is linked to neoplasm.